6-hydroxy-1-phenyl-3-{[3-(trifluoromethyl)phenyl]imino}-1,3-dihydro-2H-indol-2-one | 659726-73-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-hydroxy-1-phenyl-3-{[3-(trifluoromethyl)phenyl]imino}-1,3-dihydro-2H-indol-2-one
• 英文别名: 6-Hydroxy-1-phenyl-3-{[3-(trifluoromethyl)phenyl]imino)-1,3-dihydro-2H-indol-2-one；6-hydroxy-1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
• CAS: 659726-73-5
• 化学式: C₂₁H₁₃F₃N₂O₂
• 分子量: 382.342
• InChiKey: HKAHHRSNILDVTA-UHFFFAOYSA-N

物化性质

• 沸点：
  547.7±60.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-甲氧基二苯胺 在 三溴化硼 、 溶剂黄146 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 6-hydroxy-1-phenyl-3-{[3-(trifluoromethyl)phenyl]imino}-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  [EN] 3-IMINO-2-INDOLONES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY
  [FR] 3-IMINO-2-INDOLONES POUR TRAITER LA DEPRESSION ET/OU L'ANXIETE

  摘要：

  这项发明涉及选择性拮抗剂GalR3受体的吲哚酮衍生物。该发明提供了一种包含该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。此发明还提供了一种通过结合该发明化合物的治疗有效量和药学上可接受的载体制备的药物组合物。此发明还提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药学上可接受的载体。此发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投药一定量的该发明化合物以治疗受试者的抑郁症和/或焦虑症。此发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者投药一种包含药学上可接受的载体和GalR3受体拮抗剂的治疗有效量的组合物。

  公开号：

  WO2004014854A1

文献信息

• 3-Imino-2-indolones for the treatement of depression and/or anxiety
  申请人：——

  公开号：US20040082615A1

  公开（公告）日：2004-04-29

  This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

  这项发明涉及选择性拮抗剂GalR3受体的吲哚酮衍生物。该发明提供一种药物组合物，包括该发明的化合物的治疗有效量和药用可接受载体。该发明还提供一种通过结合该发明的化合物的治疗有效量和药用可接受载体制备的药物组合物。该发明进一步提供一种制备药物组合物的方法，包括结合该发明的化合物的治疗有效量和药用可接受载体。该发明还提供一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用足以治疗受试者抑郁症和/或焦虑症的该发明化合物的量。该发明还提供一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者施用含有药用可接受载体和治疗有效量GalR3受体拮抗剂的组合物。
• 3-imino-2-indolones for the treatment of depression and/or anxiety
  申请人：Konkel Michael

  公开号：US20050148635A1

  公开（公告）日：2005-07-07

  This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

  本发明涉及选择性GalR3受体拮抗剂的吲哚酮衍生物。本发明提供一种制药组合物，其包括本发明化合物的治疗有效量和药学可接受的载体。本发明还提供一种通过结合本发明化合物的治疗有效量和药学可接受的载体制备的制药组合物。本发明还提供一种制备制药组合物的方法，包括结合本发明化合物的治疗有效量和药学可接受的载体。本发明还提供一种治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用本发明化合物的治疗有效量。本发明还提供一种治疗受试者抑郁症和/或焦虑症的方法，其包括向受试者施用一种包括药学可接受的载体和GalR3受体拮抗剂治疗有效量的组合物。